Nexstim Plc, a medical technology company, engages in the development of non-invasive brain stimulation technologies in Finland, rest of Europe, North America, and internationally. The company’s navigated transcranial magnetic stimulation (nTMS) technology utilizes 3D navigation for providing accurate and personalized targeting of the TMS to the specific areas of the brain. It also offers Navigated Brain Therapy system, a navigated brain therapy system for the treatment of major depressive disorder (MDD) and chronic neuropathic pain; and Navigated Brain Stimulation (NBS) system, a navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. The company primarily markets and sells its diagnostics systems to universities and teaching hospitals. Nexstim Plc has a collaboration with Sinaptica Therapeutics, Inc. to develop, manufacture, and supply SinaptiStim-AD systems. The company was incorporated in 2000 and is headquartered in Helsinki, Finland.
Metrics to compare | NXTMH | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNXTMHPeersSector | |
---|---|---|---|---|
P/E Ratio | −69.6x | −1.4x | −0.6x | |
PEG Ratio | −0.95 | 0.48 | 0.00 | |
Price/Book | 31.1x | 3.1x | 2.6x | |
Price / LTM Sales | 6.2x | 2.9x | 3.1x | |
Upside (Analyst Target) | −15.0% | 16.6% | 53.1% | |
Fair Value Upside | Unlock | −0.3% | 7.5% | Unlock |